Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Sep 2025 value amounting to $81.8 million.

  • Viridian Therapeutics, Inc.\DE's Shares Outstanding (Diluted Average) rose 23.13% to $81.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.8 million, marking a year-over-year increase of 23.13%. This contributed to the annual value of $67.9 million for FY2024, which is 51.68% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Shares Outstanding (Diluted Average) of $81.8 million as of Q3 2025, which was up 0.23% from $81.6 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Shares Outstanding (Diluted Average) high stood at $81.8 million for Q3 2025, and its period low was $6.3 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $61.6 million, with a median of $63.9 million in 2024.
  • Data for Viridian Therapeutics, Inc.\DE's Shares Outstanding (Diluted Average) shows a peak YoY spiked of 312.32% (in 2022) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding (Diluted Average) (Quarterly) stood at $11.9 million in 2021, then soared by 169.22% to $32.1 million in 2022, then skyrocketed by 39.48% to $44.8 million in 2023, then skyrocketed by 51.68% to $67.9 million in 2024, then grew by 23.13% to $81.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $81.8 million for Q3 2025, versus $81.6 million for Q2 2025 and $81.3 million for Q1 2025.